{"filing":{"accession_number":"0001554855-26-001608","cik":"0000888721","ticker":"TRIB","company_name":"TRINITY BIOTECH PLC","form":"6-K","filing_date":"2026-07-22","report_date":null,"primary_document":"MainDocument.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/888721/000155485526001608/MainDocument.htm"},"events":[{"id":19353,"run_id":17414,"accession_number":"0001554855-26-001608","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"Trinity Biotech announced a strategic collaboration agreement with Latch Medical to combine CGM+ biosensor technology with intradermal drug delivery, along with a planned equity investment in Latch Medical. This is a material operational and strategic partnership that expands Trinity Biotech's product platform and market opportunity in metabolic health solutions, but does not fit the specific categories of M\u0026A activity (no acquisition/merger), equity issuance (investment is outbound, not dilutive to Trinity), or other named event types. The collaboration and investment represent a significant strategic initiative affecting the company's future direction and competitive positioning.","company_name":"TRINITY BIOTECH PLC","ticker":"TRIB","filing_date":"2026-07-22","form":"6-K","submitted_at":null,"items":[{"id":18423,"accession_number":"0001554855-26-001608","item_number":"EX-99.1","item_title":"ex991_1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Trinity Biotech announced a strategic collaboration agreement with Latch Medical to combine CGM+ biosensor technology with intradermal drug delivery, along with a planned equity investment in Latch Medical. This is a material operational and strategic partnership that expands Trinity Biotech's product platform and market opportunity in metabolic health solutions, but does not fit the specific categories of M\u0026A activity (no acquisition/merger), equity issuance (investment is outbound, not dilutive to Trinity), or other named event types. The collaboration and investment represent a significant strategic initiative affecting the company's future direction and competitive positioning.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-22T12:03:42.393757+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":18423,"accession_number":"0001554855-26-001608","item_number":"EX-99.1","item_title":"ex991_1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Trinity Biotech announced a strategic collaboration agreement with Latch Medical to combine CGM+ biosensor technology with intradermal drug delivery, along with a planned equity investment in Latch Medical. This is a material operational and strategic partnership that expands Trinity Biotech's product platform and market opportunity in metabolic health solutions, but does not fit the specific categories of M\u0026A activity (no acquisition/merger), equity issuance (investment is outbound, not dilutive to Trinity), or other named event types. The collaboration and investment represent a significant strategic initiative affecting the company's future direction and competitive positioning.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-22T12:03:42.393757+00:00","company_name":"TRINITY BIOTECH PLC","ticker":"TRIB","filing_date":"2026-07-22"}]}